A Dual Stimuli-Responsive Nanoimmunomodulator for Antitumor Synergy of Macrophages and T Cells DOI

Jun‐Ying Ding,

Xueze Zhao,

Saran Long

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 7, 2025

Only a minority of patients benefit from current T-cell-focused adaptive immunotherapies, underscoring the need to engage innate immune cells, particularly macrophages, for multilayered tumor control. However, high-efficacy therapeutics capable orchestrating multiple cells remain scarce. Herein, dual stimuli-responsive nanoimmunomodulator (6EPP@si) that caters specifically microenvironment (TME) is presented antitumor synergy macrophages and T cells. Using functional polymer-based carrier, we co-deliver endoplasmic reticulum (ER)-localized photosensitizer 6E small interfering RNA targeting CD47 (siCD47) into breast tumors. Within acidic high-glutathione TME, 6EPP@si undergoes self-lysosome escape nanocleavage precise, on-demand drug release. Consequently, siCD47 released cytoplasm enables potent silencing, while ER-targeted induces immunogenic cell death through reactive oxygen species-based ER stress, triggering release damage-associated molecular patterns, including calreticulin surface translocation. enhances macrophage phagocytosis by modulating both antiphagocytic prophagocytic signals also promotes antigen presentation activate In orthotopic spontaneous lung metastatic models, this combined approach demonstrates robust effects effective antimetastatic immunity, offering meaningful strategy simultaneously enhancing cancer immunotherapy.

Language: Английский

m5C methylation modification may be an accomplice in colorectal cancer escaping from anti-tumor effects of innate immunity-type I/III interferon DOI Creative Commons

Yiqi Sun,

Yunfei Liu, Lu Jiang

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 10, 2025

Colorectal cancer (CRC) is one of the most prevalent malignant tumors in world, and its occurrence development are closely related to complex immune regulatory mechanisms. As first barrier body's defense, innate immunity plays a key role tumor surveillance anti-tumor response, which type I/III interferon (IFN) an important mediator with significant antiviral functions. 5-methylcytosine (m5C) modification RNA epigenetic regulation that promotes expression CRC oncogenes immune-related genes. It can enhance proliferation, migration, invasion cells by affecting mRNA stability, translation efficiency, nuclear export. In addition, m5C modulates activity signaling pathways inhibits production function, further helping evade surveillance. However, there insufficient elucidations on interaction between CRC. this study, mechanism colorectal was systematically reviewed explored. This work focused how escape pathway, thereby providing new diagnostic markers therapeutic targets for clinical use, enhancing immunotherapy efficacy.

Language: Английский

Citations

0
Therapeutic role of immune cells against colon cancer DOI
Manoj Kumar Gupta,

Gayatri Gouda,

Ramakrishna Vadde

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 127 - 146

Published: Jan. 1, 2025

Language: Английский

Citations

0
Chemotherapy boosts anti-angiogenic and anti-PD-1 combination therapy through activation of cCAS-STING pathway in colon cancer DOI
Xiaofei Li,

Yu-Wen Dong,

Tingyu Wang

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 149, P. 114212 - 114212

Published: Feb. 3, 2025

Language: Английский

Citations

0
Recent advances in nanomedicine therapy for bacterial pneumonia DOI

Weiqian Jin,

Ling Liao, Tao Qin

et al.

Chinese Chemical Letters, Journal Year: 2025, Volume and Issue: unknown, P. 110920 - 110920

Published: Feb. 1, 2025

Language: Английский

Citations

0
A Dual Stimuli-Responsive Nanoimmunomodulator for Antitumor Synergy of Macrophages and T Cells DOI

Jun‐Ying Ding,

Xueze Zhao,

Saran Long

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 7, 2025

Only a minority of patients benefit from current T-cell-focused adaptive immunotherapies, underscoring the need to engage innate immune cells, particularly macrophages, for multilayered tumor control. However, high-efficacy therapeutics capable orchestrating multiple cells remain scarce. Herein, dual stimuli-responsive nanoimmunomodulator (6EPP@si) that caters specifically microenvironment (TME) is presented antitumor synergy macrophages and T cells. Using functional polymer-based carrier, we co-deliver endoplasmic reticulum (ER)-localized photosensitizer 6E small interfering RNA targeting CD47 (siCD47) into breast tumors. Within acidic high-glutathione TME, 6EPP@si undergoes self-lysosome escape nanocleavage precise, on-demand drug release. Consequently, siCD47 released cytoplasm enables potent silencing, while ER-targeted induces immunogenic cell death through reactive oxygen species-based ER stress, triggering release damage-associated molecular patterns, including calreticulin surface translocation. enhances macrophage phagocytosis by modulating both antiphagocytic prophagocytic signals also promotes antigen presentation activate In orthotopic spontaneous lung metastatic models, this combined approach demonstrates robust effects effective antimetastatic immunity, offering meaningful strategy simultaneously enhancing cancer immunotherapy.

Language: Английский

Citations

0